Top-Rated StocksTop-RatedNASDAQ:LEGN Legend Biotech (LEGN) Stock Price, News & Analysis $48.29 -5.76 (-10.66%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$47.74▼$54.3250-Day Range$44.74▼$59.8852-Week Range$38.60▼$70.78Volume2.80 million shsAverage Volume1.04 million shsMarket Capitalization$8.80 billionP/E RatioN/ADividend YieldN/APrice Target$81.78 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Legend Biotech alerts: Email Address Legend Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside69.3% Upside$81.78 Price TargetShort InterestBearish5.88% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.43Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.56) to ($0.69) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.49 out of 5 starsMedical Sector430th out of 910 stocksPharmaceutical Preparations Industry193rd out of 426 stocks 4.5 Analyst's Opinion Consensus RatingLegend Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 13 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLegend Biotech has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Legend Biotech's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.88% of the outstanding shares of Legend Biotech have been sold short.Short Interest Ratio / Days to CoverLegend Biotech has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in Legend Biotech has recently increased by 6.25%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLegend Biotech does not currently pay a dividend.Dividend GrowthLegend Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LEGN. Previous Next 1.9 News and Social Media Coverage News SentimentLegend Biotech has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Legend Biotech this week, compared to 4 articles on an average week.Search InterestOnly 5 people have searched for LEGN on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Legend Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Legend Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.02% of the stock of Legend Biotech is held by insiders.Percentage Held by Institutions70.89% of the stock of Legend Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Legend Biotech's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Legend Biotech are expected to grow in the coming year, from ($1.56) to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Legend Biotech is -37.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Legend Biotech is -37.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLegend Biotech has a P/B Ratio of 7.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Legend Biotech's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Mode MobilePre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A investment now open.Claim Exclusive 100% Bonus: $0.25/Share About Legend Biotech Stock (NASDAQ:LEGN)Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Read More LEGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LEGN Stock News HeadlinesSeptember 6 at 4:02 AM | americanbankingnews.comLegend Biotech Co. (NASDAQ:LEGN) Given Average Recommendation of "Buy" by BrokeragesSeptember 4 at 1:13 AM | americanbankingnews.comShort Interest in Legend Biotech Co. (NASDAQ:LEGN) Expands By 6.3%September 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. September 3, 2024 | finance.yahoo.comMatthews Emerging Markets Small Companies Fund Boosts Stake in Legend Biotech CorpAugust 30, 2024 | americanbankingnews.comHC Wainwright Reiterates Buy Rating for Legend Biotech (NASDAQ:LEGN)August 28, 2024 | benzinga.comBeyond The Numbers: 14 Analysts Discuss Legend Biotech StockAugust 20, 2024 | globenewswire.comLegend Biotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 14, 2024 | finance.yahoo.comHere's What Analysts Are Forecasting For Legend Biotech Corporation (NASDAQ:LEGN) After Its Second-Quarter ResultsSeptember 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. August 12, 2024 | markets.businessinsider.comStrong Market Acceptance and Strategic Growth Potential Justify Buy Rating for Legend BiotechAugust 11, 2024 | seekingalpha.comLegend Biotech Corporation (LEGN) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | seekingalpha.comLegend Biotech Corporation 2024 Q2 - Results - Earnings Call PresentationAugust 9, 2024 | globenewswire.comLegend Biotech Reports Second Quarter 2024 Results and Recent HighlightsAugust 8, 2024 | msn.comLegend Biotech Q2 2024 Earnings PreviewJuly 30, 2024 | seekingalpha.comLegend Biotech's Promising CAR-T Therapies Face Valuation And Cash Burn ChallengesJuly 29, 2024 | msn.comIs Legend Biotech Corporation (LEGN) a Good Growth Stock to Buy?July 27, 2024 | msn.comLegend Biotech expects adj. loss of ~$102.2M in 1H24July 26, 2024 | globenewswire.comLegend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024See More Headlines Receive LEGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Legend Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/09/2024Today9/07/2024Next Earnings (Estimated)11/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LEGN CUSIPN/A CIK1801198 Webwww.legendbiotech.com Phone732-317-5050FaxN/AEmployees1,800Year FoundedN/APrice Target and Rating Average Stock Price Target$81.78 High Stock Price Target$94.00 Low Stock Price Target$60.00 Potential Upside/Downside+69.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($1.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-518,250,000.00 Net Margins-62.50% Pretax Margin-182.41% Return on Equity-23.20% Return on Assets-15.70% Debt Debt-to-Equity Ratio0.25 Current Ratio4.84 Quick Ratio4.78 Sales & Book Value Annual Sales$455.99 million Price / Sales19.30 Cash FlowN/A Price / Cash FlowN/A Book Value$6.36 per share Price / Book7.59Miscellaneous Outstanding Shares182,283,000Free Float182,247,000Market Cap$8.80 billion OptionableOptionable Beta0.11 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Ying Huang Ph.D. (Age 51)CEO & Director Ms. Lori A. Macomber CPA (Age 53)Chief Financial Officer Mr. Doug WallaceVice President of Global OperationsDr. Guowei Fang Ph.D.Chief Scientific Officer & Head of Business DevelopmentJoanne ChoiSenior Manager of Investor RelationsMr. James Pepin J.D.General CounselDeborah WongExecutive Director of Strategic Marketing & Corporate CommunicationsMs. Elaine QianVP & Global Head of Human ResourcesDr. Yuhong Qiu Ph.D.Senior Vice President of Global Regulatory AffairsMr. Steven J. GavelSenior Vice President of Commercial Development, US & EuropeMore ExecutivesKey CompetitorsEidos TherapeuticsNASDAQ:EIDXPrincipia BiopharmaNASDAQ:PRNBAutolus TherapeuticsNASDAQ:AUTLbluebird bioNASDAQ:BLUEModernaNASDAQ:MRNAView All CompetitorsInstitutional OwnershipSenator Investment Group LPSold 10,000 shares on 8/20/2024Ownership: 0.085%Point72 Asset Management L.P.Bought 304,520 shares on 8/19/2024Ownership: 0.167%Quarry LPBought 8,800 shares on 8/16/2024Ownership: 0.005%Decheng Capital LLCBought 12,195 shares on 8/15/2024Ownership: 0.054%Point72 Europe London LLPBought 22,245 shares on 8/15/2024Ownership: 0.012%View All Institutional Transactions LEGN Stock Analysis - Frequently Asked Questions How have LEGN shares performed this year? Legend Biotech's stock was trading at $60.17 on January 1st, 2024. Since then, LEGN stock has decreased by 19.7% and is now trading at $48.29. View the best growth stocks for 2024 here. How were Legend Biotech's earnings last quarter? Legend Biotech Co. (NASDAQ:LEGN) released its quarterly earnings data on Friday, August, 9th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.49. The business's revenue for the quarter was up 154.4% compared to the same quarter last year. When did Legend Biotech IPO? Legend Biotech (LEGN) raised $350 million in an IPO on Friday, June 5th 2020. The company issued 18,400,000 shares at $18.00-$20.00 per share. Morgan Stanley, J.P. Morgan Securities and Jefferies acted as the underwriters for the IPO. Who are Legend Biotech's major shareholders? Legend Biotech's top institutional shareholders include Massachusetts Financial Services Co. MA (1.08%), Federated Hermes Inc. (0.85%), Tri Locum Partners LP (0.20%) and Point72 Asset Management L.P. (0.17%). How do I buy shares of Legend Biotech? Shares of LEGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Legend Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Legend Biotech investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), CrowdStrike (CRWD), Lam Research (LRCX), ServiceNow (NOW), Peloton Interactive (PTON) and QUALCOMM (QCOM). This page (NASDAQ:LEGN) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Legend Biotech Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Legend Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.